Jpmorgan Chase & CO Cti Biopharma Corp Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 18, 2023	BUY	$4.2 - $6.01 $322,165 - $461,003	76,706 Added 7.32%	1,124,714 $4.72 Million
Q1 2023 May 11, 2023	SELL	$4.2 - $6.01 $579,692 - $829,512	-138,022 Reduced 11.64%	1,048,008 $4.4 Million
Q4 2022 Feb 13, 2023	BUY	$4.45 - $6.17 $208,794 - $289,496	46,920 Added 4.12%	1,186,030 $7.13 Million
Q3 2022 Nov 14, 2022	SELL	$5.36 - $7.43 $175,079 - $242,693	-32,664 Reduced 2.79%	1,139,110 $6.63 Million
Q2 2022 Aug 11, 2022	BUY	$3.55 - $6.27 $4.15 Million - $7.32 Million	1,167,902 Added 30162.76%	1,171,774 $7 Million

Q1 2022 May 11, 2022	SELL	$1.9 - $5.23 $8,418 - $23,174	-4,431 Reduced 53.37%	3,872 $18,000
Q4 2021 Feb 10, 2022	BUY	$1.44 - $2.86 $1,468 - $2,917	1,020 Added 14.01%	8,303 $21,000
Q3 2021 Nov 12, 2021	BUY	$2.25 - $3.18 $16,386 - $23,159	7,283 New	7,283 $21,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.